Metraipolis › archive › dc_d437d26cda7b

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes — Europe PMC PMID:41800058

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41800058
DOI
10.3389/fonc.2026.1759702
License (as archived)
solo-consultazione
Archived
2026-11-05T14:03:17.510Z
SHA-256 of the archived text
e2a365db8948efc06b12d3338a521a661c6d46d7e1444019da828234212e0d70
Stable URL of this page
https://metraipolis.com/documento/dc_d437d26cda7b

How to cite

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes — Europe PMC PMID:41800058 — Europe PMC (en), https://europepmc.org/article/MED/41800058 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d437d26cda7b (Metraipolis archive dc_d437d26cda7b, sha256 e2a365db8948efc06b12d3338a521a661c6d46d7e1444019da828234212e0d70)
BibTeX
@misc{dcd437d26cda7b,
  title = {The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes — Europe PMC PMID:41800058},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41800058},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d437d26cda7b; sha256 e2a365db8948efc06b12d3338a521a661c6d46d7e1444019da828234212e0d70},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41800058. Agents can read the archived copy with the MCP tool read_document.